Preliminary Clinical Assessment of I.C.R.F. 159 in Acute Leukaemia and LymphosarcomaBr Med J 1969; 1 doi: https://doi.org/10.1136/bmj.1.5647.822 (Published 29 March 1969) Cite this as: Br Med J 1969;1:822
- K. Hellmann,
- K. A. Newton,
- D. N. Whitmore,
- I. W. F. Hanham,
- Jane V. Bond
I.C.R.F. 159, a new antitumour agent, has been assessed in six patients with acute leukaemia and three with lymphosarcoma. In all but two there was a considerable fall in circulating primitive cells, and in one there was bone-marrow evidence of a partial remission. Severe toxic effects were seen in only one case; they consisted of alopecia and gastroenteritis. It is suggested that I.C.R.F. 159 is worth further examination in all forms of acute leukaemia and lymphosarcoma.
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial